Published in J Neural Transm (Vienna) on August 22, 2014
Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci (1990) 8.61
The role of executive function and attention in gait. Mov Disord (2008) 5.03
Forward modeling allows feedback control for fast reaching movements. Trends Cogn Sci (2000) 3.66
Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol (2009) 2.28
Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann Neurol (1992) 1.86
A review of differences between basal ganglia and cerebellar control of movements as revealed by functional imaging studies. Brain (1998) 1.83
Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Mov Disord (2008) 1.72
Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol (1995) 1.70
A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology (1988) 1.57
Neural circuits and functional organization of the striatum. J Neurol (2000) 1.56
Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord (2000) 1.40
Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl (1999) 1.34
Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back. Mov Disord (2002) 1.34
The modified bradykinesia rating scale for Parkinson's disease: reliability and comparison with kinematic measures. Mov Disord (2011) 1.27
Motor subcircuits mediating the control of movement extent and speed. J Neurophysiol (2003) 1.24
Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord (2003) 1.19
Single cell studies of the primate putamen. II. Relations to direction of movement and pattern of muscular activity. Exp Brain Res (1984) 1.14
Impairments of speed and amplitude of movement in Parkinson's disease: a pilot study. Mov Disord (2009) 1.12
Parametric mapping of [18F]FPCIT binding in early stage Parkinson's disease: a PET study. Synapse (2002) 1.11
Parametric analysis of rate-dependent hemodynamic response functions of cortical and subcortical brain structures during auditorily cued finger tapping: a fMRI study. Neuroimage (2003) 1.11
Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's disease. Mov Disord (2011) 1.09
Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease. Brain (2012) 1.08
Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video study. J Neurol Neurosurg Psychiatry (2010) 1.08
Somatotopy in the basal ganglia: experimental and clinical evidence for segregated sensorimotor channels. Brain Res Brain Res Rev (2005) 1.07
Performance of repetitive wrist movements in Parkinson's disease. Brain (1992) 1.00
Neural correlates of performance variability during motor sequence acquisition. Neuroimage (2011) 0.91
Which motor disorder in Parkinson's disease indicates the true motor function of the basal ganglia? Ciba Found Symp (1984) 0.91
Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease. J Neurol Neurosurg Psychiatry (1999) 0.91
Gait and upper limb variability in Parkinson's disease patients with and without freezing of gait. J Neurol (2013) 0.87
Striatal dopamine loss and discriminative sensory dysfunction in Parkinson's disease. Acta Neurol Scand (2012) 0.87
Effects of reversible blockade of basal ganglia on a voluntary arm movement. J Neurophysiol (1992) 0.86
Multisensory responses and receptive field properties of neurons in the substantia nigra and in the caudate nucleus. Eur J Neurosci (2005) 0.83
Impaired somatosensory discrimination of shape in Parkinson's disease: association with caudate nucleus dopaminergic function. Hum Brain Mapp (1999) 0.81
Function of caudate neurons during limb movements in awake primates. Brain Res (1979) 0.81
The pattern of striatal dopaminergic denervation explains sensorimotor synchronization accuracy in Parkinson's disease. Behav Brain Res (2013) 0.81
Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease. Neurol Sci (2009) 0.80
Delineating the whole brain BOLD response to passive movement kinematics. IEEE Int Conf Rehabil Robot (2013) 0.78
Comparing kinematic changes between a finger-tapping task and unconstrained finger flexion-extension task in patients with Parkinson's disease. Exp Brain Res (2013) 0.78
Estimation of further disease progression of Parkinson's disease by dopamin transporter scan vs clinical rating. Parkinsonism Relat Disord (2011) 0.78
Sensory-motor processing in the caudate nucleus and globus pallidus: a single-unit study in behaving primates. Can J Physiol Pharmacol (1980) 0.77
Chorea associated with non-ketotic hyperglycemia and hyperintensity basal ganglia lesion on T1-weighted brain MRI study: a meta-analysis of 53 cases including four present cases. J Neurol Sci (2002) 3.96
Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology (2009) 3.49
The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry (1998) 2.88
PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology (2007) 2.63
Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology (2009) 2.27
Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry (2008) 2.12
Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology (2006) 1.85
A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab (2012) 1.59
In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain (2013) 1.57
Validity of clinical diagnosis in dementia: a prospective clinicopathological study. J Neurol Neurosurg Psychiatry (1985) 1.54
Fluoxetine administered to juvenile monkeys: effects on the serotonin transporter and behavior. Am J Psychiatry (2014) 1.54
In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology (2009) 1.47
Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol (2000) 1.41
PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord (2008) 1.39
Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. Am J Psychiatry (1998) 1.39
Application of calibrated image-derived input function to a clinical protocol. Nucl Med Commun (2014) 1.38
Role of the dopaminergic system in chronic pain -- a fluorodopa-PET study. Pain (2001) 1.37
PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain (2008) 1.34
Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology (2011) 1.26
Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. J Neurol Neurosurg Psychiatry (2004) 1.24
C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol Psychiatry (2004) 1.23
Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain (2001) 1.22
An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology (2000) 1.22
Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone. J Nucl Med (2000) 1.14
Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord (2001) 1.13
Sex differences in extrastriatal dopamine d(2)-like receptors in the human brain. Am J Psychiatry (2001) 1.11
Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J Neurol Sci (1997) 1.07
Variant Alzheimer's disease with spastic paraparesis: clinical characterization. Neurology (2000) 1.06
The pedunculopontine nucleus: its role in the genesis of movement disorders. Yonsei Med J (2000) 1.06
Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. Neurogenetics (2008) 1.05
Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus. Neurosci Lett (2001) 1.03
The Glu318Gly mutation of the presenilin-1 gene does not necessarily cause Alzheimer's disease. Ann Neurol (1998) 1.03
Decreased striatal dopamine transporter density in JNCL patients with parkinsonian symptoms. Neurology (2000) 1.01
Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy. Brain (2008) 1.01
Interaction between estrogen receptor 1 and the epsilon4 allele of apolipoprotein E increases the risk of familial Alzheimer's disease in women. Neurosci Lett (2000) 1.00
Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology (2000) 1.00
Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease. Acta Neuropathol (1998) 0.99
Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT. Ann Neurol (2000) 0.99
Personality traits and brain dopaminergic function in Parkinson's disease. Proc Natl Acad Sci U S A (2001) 0.99
An altered histaminergic innervation of the substantia nigra in Parkinson's disease. Exp Neurol (2000) 0.98
Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord (1990) 0.98
Mapping brain structure and personality in late adulthood. Neuroimage (2004) 0.96
Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease. Neurobiol Dis (2001) 0.95
Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther (2009) 0.94
Association of mutations in the glucocerebrosidase gene with Parkinson disease in a Korean population. Neurosci Lett (2012) 0.94
Impaired finger dexterity in patients with parkinson's disease correlates with discriminative cutaneous sensory dysfunction. Mov Disord (2010) 0.94
Semantic processing of spoken words in Alzheimer's disease: an electrophysiological study. J Cogn Neurosci (1998) 0.94
Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study. J Cereb Blood Flow Metab (2000) 0.93
123I-IPT brain SPECT study in essential tremor and Parkinson's disease. Neurology (1999) 0.93
Positron emission tomography with [18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients. Eur J Neurol (2013) 0.92
Unbiased morphometrical measurements show loss of pigmented nigral neurones with ageing. Neuropathol Appl Neurobiol (1999) 0.92
[11 C]Flumazenil binding in the medial temporal lobe in patients with temporal lobe epilepsy: correlation with hippocampal MR volumetry, T2 relaxometry, and neuropathology. Neurology (2000) 0.92
Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol (2001) 0.91
Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. Eur J Neurosci (2003) 0.90
Visual object recognition in early Alzheimer's disease: deficits in semantic processing. Acta Neurol Scand (2003) 0.90
Slowing of information processing in Parkinson's disease. Brain Cogn (1993) 0.90
Primary progressive freezing gait in a patient with CO-induced parkinsonism. Mov Disord (2010) 0.89
Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET. Neuroimage (2012) 0.89
Phenotype of a homozygous CADASIL patient in comparison to 9 age-matched heterozygous patients with the same R133C Notch3 mutation. Stroke (2001) 0.88
Cell counts in the substantia nigra: a comparison of single section counts and disector counts in patients with Parkinson's disease and in controls. Neuropathol Appl Neurobiol (1995) 0.88
Extrastriatal dopamine D(2) receptors in Parkinson's disease: a longitudinal study. J Neural Transm (Vienna) (2003) 0.87
A quantitative morphometrical study of neuron degeneration in the substantia nigra in Parkinson's disease. J Neurol Sci (1996) 0.87
Dystonia after head trauma. Neurology (1994) 0.86
Neuritic degeneration in the hippocampus and amygdala in Parkinson's disease in relation to Alzheimer pathology. Acta Neuropathol (1999) 0.86
Association and causal relationship of midlife obesity and related metabolic disorders with old age cognition. Curr Alzheimer Res (2011) 0.86
Neuronal size and density in the nucleus basalis of Meynert in Alzheimer's disease. J Neurol Sci (1987) 0.86
PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology (2000) 0.85
Left hemisphere activation during processing of morphologically complex word forms in adults. Neurosci Lett (1999) 0.85
Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J Neural Transm Park Dis Dement Sect (1995) 0.85
Autonomic dysfunction in recent onset and advanced Parkinson's disease. Clin Neurol Neurosurg (1988) 0.85
Hippocampal MRI volumetry in cognitively discordant monozygotic twin pairs. J Neurol Neurosurg Psychiatry (2004) 0.85
[11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment. Eur J Nucl Med Mol Imaging (2013) 0.83
Rhabdomyolysis induced by severe levodopa induced dyskinesia in a patient with Parkinson's disease. J Neurol (2011) 0.83
CADASIL: hereditary disease of arteries causing brain infarcts and dementia. Neuropathol Appl Neurobiol (1999) 0.83
Do carriers of POLG mutation W748S have disease manifestations? Clin Genet (2007) 0.81
Single section and disector counts in evaluating neuronal loss from the substantia nigra in patients with Parkinson's disease. Neuropathol Appl Neurobiol (1995) 0.81
Dopaminergic neurotransmission in chronic herpes simplex virus brain infection in rabbits. J Neural Transm Gen Sect (1993) 0.81
[18F]fluorodopa PET shows striatal dopaminergic dysfunction in juvenile neuronal ceroid lipofuscinosis. J Neurol Neurosurg Psychiatry (1997) 0.80
Decrease in mesencephalic dopamine autoreceptors in experimental herpes simplex encephalitis. J Neural Transm Gen Sect (1992) 0.80
Apolipoprotein E epsilon4 allele frequency is increased in Parkinson's disease only with co-existing Alzheimer pathology. Acta Neuropathol (1998) 0.80
Five-year follow-up of 11C-PIB uptake in Alzheimer's disease and MCI. Eur J Nucl Med Mol Imaging (2013) 0.80
Population-based input function modeling for [(18)F]FMPEP-d 2, an inverse agonist radioligand for cannabinoid CB1 receptors: validation in clinical studies. PLoS One (2013) 0.80
Risk for Parkinson's disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET. J Neurol (2000) 0.80
Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome, A [11C]diprenorphine PET study. Brain (1995) 0.79
Perceptual priming in Alzheimer's and Parkinson's diseases. Neuropsychologia (1996) 0.79
Association of an interleukin 1B gene polymorphism (-511) with Parkinson's disease in Finnish patients. J Med Genet (2002) 0.79
The effect of age on motor deficits and cerebral glucose metabolism of Parkinson's disease. Acta Neurol Scand (2010) 0.78
Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease. Q J Nucl Med Mol Imaging (2011) 0.78
Brain dopamine D-2 receptors in senile dementia. J Neural Transm (1986) 0.78
PET studies on brain monoamine transporters with carbon-11-beta-CIT in Parkinson's disease. J Nucl Med (1995) 0.78
Picture naming deficits in vascular dementia and Alzheimer's disease. J Clin Exp Neuropsychol (1997) 0.78
[18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Neurology (1992) 0.78
Imaging evidence of nigral damage in dystonia secondary to disulfiram intoxication. Mov Disord (2011) 0.78
Muscarinic and dopaminergic receptors in the aging human brain. Brain Res (1987) 0.78
Reduction in muscarinic receptor binding in limbic areas of Alzheimer brain. J Neurol Neurosurg Psychiatry (1984) 0.78
Dopamine D-1 receptors in the parkinsonian brain. Brain Res (1985) 0.78
A favorable response to antiparkinsonian treatment in juvenile neuronal ceroid lipofuscinosis. Neurology (2001) 0.78
Cholinergic dysfunction after traumatic brain injury: preliminary findings from a PET study. Neurology (2011) 0.77